L-carnitine therapy (50 mg/kilogram-bodyweight/day) administered for 3-months significantly improved several clinical measurements of ASD severity [ 1], but subsequent studies are recommended.
Haemodialysis was initiated to decrease the high serum VPA concentration and L-carnitine therapy (50 mg/kg per day for 4 days) was empirically started.
Involuntary movements, or dyskinesias, represent a debilitating complication of L-3,4-dihydroxyphenylalanine (L-dopa) therapy for Parkinson's disease (PD), experienced, ultimately, by the vast majority of the patients [1].
L- NG-monomethyl L-arginine therapy in NZB/W mice that were already suffering from nephritis had a similar but less profound effect on proteinuria and renal histopathology than did preventative therapy [ 97].
Compounding these limitations, L-DOPA therapy tends to lose effectiveness over time, L-DOPA-induced dyskinesias are a common complication of chronic dopaminergic therapy, and metabolites of this compound are neurotoxic [1].
In mice lacking cell surface expression of L-selectin, death from endotoxin is largely prevented [ 34] and anti-L-selectin therapy prevents endotoxin-induced leukocyte sequestration [ 35].
Raetz, E. A. & Salzer, W. L. Tolerability and efficacy of L-asparaginase therapy in pediatric patients with acute lymphoblastic leukemia.
